JOP20190183B1 - معدِلات مستقبلات الاستروجين - Google Patents

معدِلات مستقبلات الاستروجين

Info

Publication number
JOP20190183B1
JOP20190183B1 JOP/2019/0183A JOP20190183A JOP20190183B1 JO P20190183 B1 JOP20190183 B1 JO P20190183B1 JO P20190183 A JOP20190183 A JO P20190183A JO P20190183 B1 JOP20190183 B1 JO P20190183B1
Authority
JO
Jordan
Prior art keywords
estrogen receptor
receptor modulators
formula
disorders
processes
Prior art date
Application number
JOP/2019/0183A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
James Stewart Scott
Thomas Andrew MOSS
Johannes Wilhelmus Maria Nissink
Samantha Jayne HUGHES
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of JOP20190183A1 publication Critical patent/JOP20190183A1/ar
Application granted granted Critical
Publication of JOP20190183B1 publication Critical patent/JOP20190183B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات بالصيغة (I) صورة (I) وبأملاح مقبولة صيدلانياً منها، بعمليات ومركبات وسيطة تستخدم لتحضيرها، بتركيبات صيدلانية تحتوي عليها وباستخدامها في معالجة اضطرابات التكاثر الخلوي. الصيغة I
JOP/2019/0183A 2017-01-30 2018-01-29 معدِلات مستقبلات الاستروجين JOP20190183B1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762451971P 2017-01-30 2017-01-30
US201762523695P 2017-06-22 2017-06-22
US201762560304P 2017-09-19 2017-09-19
US201762592485P 2017-11-30 2017-11-30
PCT/EP2018/052040 WO2018138303A1 (en) 2017-01-30 2018-01-29 Estrogen receptor modulators

Publications (2)

Publication Number Publication Date
JOP20190183A1 JOP20190183A1 (ar) 2019-07-28
JOP20190183B1 true JOP20190183B1 (ar) 2022-09-15

Family

ID=61223883

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0183A JOP20190183B1 (ar) 2017-01-30 2018-01-29 معدِلات مستقبلات الاستروجين

Country Status (35)

Country Link
US (3) US10221173B2 (ar)
EP (2) EP3689873B1 (ar)
JP (1) JP6951451B2 (ar)
KR (1) KR102246668B1 (ar)
CN (1) CN110214140B (ar)
AU (1) AU2018211495B2 (ar)
CL (1) CL2019001991A1 (ar)
CO (1) CO2019008941A2 (ar)
CR (1) CR20190379A (ar)
CY (1) CY1122731T1 (ar)
DK (1) DK3494116T3 (ar)
DO (1) DOP2019000183A (ar)
EC (1) ECSP19062381A (ar)
ES (2) ES2931320T3 (ar)
HU (1) HUE047761T2 (ar)
IL (1) IL268263B (ar)
JO (1) JOP20190183B1 (ar)
LT (1) LT3494116T (ar)
MA (1) MA52555A (ar)
MX (1) MX2019008438A (ar)
MY (1) MY196317A (ar)
NI (1) NI201900080A (ar)
PE (1) PE20191500A1 (ar)
PH (1) PH12019501724A1 (ar)
PL (1) PL3494116T3 (ar)
PT (1) PT3494116T (ar)
RS (1) RS59770B1 (ar)
SG (1) SG11201906767XA (ar)
SI (1) SI3494116T1 (ar)
SM (1) SMT202000010T1 (ar)
TN (1) TN2020000009A1 (ar)
TW (1) TWI794205B (ar)
UA (1) UA125043C2 (ar)
WO (1) WO2018138303A1 (ar)
ZA (1) ZA201904696B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102479822B1 (ko) 2016-02-05 2022-12-21 인벤티스바이오 엘엘씨 선택적 에스트로겐 수용체 분해제 및 이들의 용도
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
TWI915239B (zh) * 2018-06-21 2026-02-11 瑞士商赫孚孟拉羅股份公司 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法
US20220370625A1 (en) * 2019-09-19 2022-11-24 Totus Medicines Inc. Therapeutic conjugates
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN115557920B (zh) * 2022-09-22 2024-02-20 吉林奥来德光电材料股份有限公司 一种发光辅助材料、其制备方法及有机电致发光器件

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP4555547B2 (ja) 2000-08-10 2010-10-06 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
EP1746157A4 (en) * 2004-04-27 2009-02-18 Chugai Pharmaceutical Co Ltd PROCESS FOR PLASMA CELL PROGRAMMING
WO2006101434A1 (en) 2005-03-22 2006-09-28 Astrazeneca Ab NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
PE20160874A1 (es) 2013-05-28 2016-09-04 Astrazeneca Ab Compuestos quimicos
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
WO2014205138A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
JP2017538727A (ja) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
EP3303326B1 (en) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
KR20180012853A (ko) 2015-06-16 2018-02-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
CN108349952A (zh) 2015-11-09 2018-07-31 豪夫迈·罗氏有限公司 四氢萘雌激素受体调节剂及其用途
CA3011391C (en) 2015-11-12 2021-02-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
HK1244808A1 (zh) 2015-12-22 2018-08-17 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
US9969732B2 (en) 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
CN109415388A (zh) 2016-05-06 2019-03-01 路易斯安那泽维尔大学 选择性雌激素受体下调剂(serds)
CN109415361B (zh) 2016-06-29 2022-03-08 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
US10149839B2 (en) * 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
ES2975558T3 (es) 2016-09-15 2024-07-09 Arvinas Inc Derivados de indol como degradantes de receptor de estrógeno
JOP20190090B1 (ar) 2016-10-24 2023-03-28 Astrazeneca Ab مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
PH12019501328B1 (en) 2016-12-16 2023-05-12 Lilly Co Eli 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN110325530B (zh) 2016-12-16 2022-01-11 辉瑞大药厂 Glp-1受体激动剂及其用途
GEP20207202B (en) 2017-01-30 2020-12-25 Chiesi Farm Spa Tyrosine amide derivatives as rho-kinase inhibitors

Also Published As

Publication number Publication date
PT3494116T (pt) 2020-01-28
SMT202000010T1 (it) 2020-03-13
US11046689B2 (en) 2021-06-29
US20180282325A1 (en) 2018-10-04
KR20190112767A (ko) 2019-10-07
LT3494116T (lt) 2020-01-10
NI201900080A (es) 2020-03-18
AU2018211495B2 (en) 2020-05-21
CN110214140B (zh) 2022-08-30
KR102246668B1 (ko) 2021-04-29
UA125043C2 (uk) 2021-12-29
JOP20190183A1 (ar) 2019-07-28
ECSP19062381A (es) 2019-09-30
US20200239468A1 (en) 2020-07-30
US20190233413A1 (en) 2019-08-01
IL268263A (en) 2019-09-26
EP3689873A1 (en) 2020-08-05
PH12019501724A1 (en) 2020-06-01
CR20190379A (es) 2019-10-21
CY1122731T1 (el) 2021-05-05
TW201840558A (zh) 2018-11-16
CO2019008941A2 (es) 2019-08-30
ZA201904696B (en) 2020-05-27
MA52555A (fr) 2021-03-17
CL2019001991A1 (es) 2019-10-11
BR112019015389A2 (pt) 2020-03-10
SG11201906767XA (en) 2019-08-27
JP6951451B2 (ja) 2021-10-20
HUE047761T2 (hu) 2020-05-28
JP2020505354A (ja) 2020-02-20
SI3494116T1 (sl) 2020-02-28
PL3494116T3 (pl) 2020-04-30
EP3494116A1 (en) 2019-06-12
AU2018211495A1 (en) 2019-09-12
ES2931320T3 (es) 2022-12-28
DK3494116T3 (da) 2020-01-27
PE20191500A1 (es) 2019-10-22
MX2019008438A (es) 2019-10-30
RS59770B1 (sr) 2020-02-28
IL268263B (en) 2021-10-31
ES2766249T3 (es) 2020-06-12
CN110214140A (zh) 2019-09-06
US10590132B2 (en) 2020-03-17
TWI794205B (zh) 2023-03-01
US10221173B2 (en) 2019-03-05
WO2018138303A1 (en) 2018-08-02
EP3689873B1 (en) 2022-09-14
DOP2019000183A (es) 2019-07-31
CA3050337A1 (en) 2018-08-02
MY196317A (en) 2023-03-24
EP3494116B1 (en) 2019-10-23
TN2020000009A1 (en) 2021-10-04

Similar Documents

Publication Publication Date Title
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
JOP20190183A1 (ar) معدِلات مستقبلات الاستروجين
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
NZ737399A (en) Ccr2 modulators
PH12021550048A1 (en) Selective estrogen receptor degraders.
TW201613864A (en) Novel compounds
MX391392B (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201992679A1 (ru) N-замещенные индольные производные
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
MX377481B (es) Derivados de serina como agonistas del receptor de grelina.
EA201991734A1 (ru) Модуляторы рецептора эстрогена
EA202092600A1 (ru) Тетрациклические гетероарильные соединения